Contact: Patricia A.  Spinella
Investor Relations
(201) 847-5453
Email: patricia_spinella@bd.com

Colleen T.  White
Corporate Communications
(201) 847-5369
Email: colleen_white@bd.com

Franklin Lakes, NJ (March 26, 2008)) – BD (Becton, Dickinson and Company) (NYSE:BDX), a global medical technology company, announced today that it would present at the Leerink Swann Molecular Diagnostics Roundtable Conference on Thursday, April 3, 2008 at 10:10 a.m. (ET).

The live webcast of BD’s presentation can be accessed from the BD corporate website at www.bd.com/investors and will be available for replay through Thursday, April 10, 2008.

BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people’s health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.